Red Light Holland's Wholly Owned Subsidiary Happy Caps Expands Safeway Partnership to 123 Stores Across the U.S. Pacific Northwest, in Time for American Thanksgiving
Toronto, Ontario--(Newsfile Corp. - November 11, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, is pleased to announce a major U.S. retail expansion milestone for its wholly owned subsidiary, 4316747 Nova Scotia Limited o/a Happy Caps Mushroom Farm ("Happy Caps") with Albertso
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-11-11 8:39 AM EST | Red Light Holland Corp.
Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal
Dublin, Ireland--(Newsfile Corp. - November 11, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership. Cosmo’s 2025 S&P Global Corporate Sustainability Assessment has been upgraded to the 67th percentile, a significant improvement from la
Healthcare and Hospitals, Health
2025-11-11 1:01 AM EST | Cosmo Pharmaceuticals N.V.
CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000. The
Technology, Healthcare and Hospitals, Health
2025-11-10 11:37 PM EST | CardioComm Solutions, Inc.
LevelJump Announces 2025 Third Quarter Results
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and nine months ended September 30, 2025. Financial and Operational Highlights Revenues were $4.84 million in the third quarter compared to $4.45 million in the same period the prior year, an increase of 8.7%. For the nine months ended S
Healthcare and Hospitals, Health
2025-11-10 10:31 PM EST | LevelJump Healthcare Corp.
BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the closing of its previously announced underwritten public offering of 2,846,854 shares of common stock, no par value, and at a public offering price of $7.00 per share, which includes 361,854 shares issued upon the exercise by the
Biotechnology, Pharmaceuticals, Health
2025-11-10 4:18 PM EST | BioHarvest Sciences Inc.
Game-Changing Alliance: Adia Labs and Axia
Winter Park, Florida--(Newsfile Corp. - November 10, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today announced a strategic partnership between its research and development division, Adia Labs, and AxiaMD, a premier provider of nationwide physician oversight and compliance services for med spas, IV clinics, physician assistants, nurse practitioners, and wellness practices. Under the agreement, AxiaMD's extensive network
Healthcare and Hospitals, Health
2025-11-10 9:00 AM EST | Adia Nutrition Inc.
Functional Brands Inc. and Market Performance Group Forge High-Impact Partnership to Supercharge Growth of Kirkman(R) Brand in the Expanding Health & Wellness Market
Lake Oswego, Oregon--(Newsfile Corp. - November 10, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, is thrilled to announce a new commercial partnership with Market Performance Group (MPG), a top-tier omnichannel commerce agency known for driving exponential growth for leading consumer brands. This strategic collaboration marks an exciting new chapter for the Kirkman® brand-one of the most trusted names in nutritional supplem
Household / Consumer / Cosmetics, Health
2025-11-10 8:00 AM EST | Functional Brands Inc.
Delivra Health Brands Reports Financial Results for First Quarter of Fiscal 2026 Highlighting Continued Growth of Dream Water (R) and LivRelief(TM)
Growth of Dream Water® US and Canada by 8% compared to same quarter last year Growth of Dream Water® E-commerce by 74% compared to same quarter last year Growth of LivRelief™ by 9% compared to same quarter last year Growth of LivRelief™ E-commerce by 16% compared to same quarter last year Vancouver, British Co
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2025-11-10 7:25 AM EST | Delivra Health Brands Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating re
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-10 7:00 AM EST | Elite Pharmaceuticals, Inc.
LevelJump Announces Receipt of Notice of Requisition for a Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - November 7, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that a notice of requisition of a meeting of shareholders (the "Requisition") was delivered to the registered office of the Company on November 3, 2025. The Requisition has been made by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders") which requires that the Company call and hold a meeting of shareholders pursuant to s
Healthcare and Hospitals, Health
2025-11-07 5:00 PM EST | LevelJump Healthcare Corp.
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Ma
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 10:30 AM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award. This is the fifth annual BioTech Breakthrough Awards program conducted by
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 7:45 AM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of $7.00 per share. BioHarvest expects the gross proceeds from this offering to be approximately $17.4 m
Biotechnology, Pharmaceuticals, Health
2025-11-07 7:30 AM EST | BioHarvest Sciences Inc.
BioHarvest Announces Proposed Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, BioHarvest also expects to grant the underwriter a 30-day option to purchase up to an additional
Biotechnology, Pharmaceuticals, Health
2025-11-06 4:37 PM EST | BioHarvest Sciences Inc.
James Anderson Provides Update on Holdings of Myndtec Inc.
Detroit, Michigan--(Newsfile Corp. - November 6, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On November 4, 2025, the Issuer completed the seventh tranche (the "Seventh Tranche") of a private placement of units ("Units") announced on January 30, 2025. 262,027 Units
Technology, Healthcare and Hospitals, Health
2025-11-06 4:30 PM EST | James Anderson
Neural's Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, in which it owns 30.75% int
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-06 8:46 AM EST | Neural Therapeutics Inc.
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025). The presentation generated exceptional interest from both the scientific a
Biotechnology, Pharmaceuticals, Health
2025-11-06 3:15 AM EST | Defence Therapeutics Inc.
Adia Nutrition Inc. Announces Transformative 2025 Milestones and Strategic Progress Toward Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - November 5, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today recaps its pivotal year-to-date achievements, marked by explosive revenue growth, strategic divestitures, and decisive steps toward full SEC reporting and a Nasdaq listing. 2025 Key Milestones Q3 Revenue Surges Over 200% Quarter-Over-Quarter: On October 8, preliminary results sh
Healthcare and Hospitals, Health
2025-11-05 10:00 AM EST | Adia Nutrition Inc.
Functional Brands Secures Direct Listing on the Nasdaq Capital Market Under the Symbol MEHA
Lake Oswego, Oregon--(Newsfile Corp. - November 5, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, announced today that it has received approval to list its shares on the Nasdaq under the symbol (NASDAQ: MEHA). The company expects its shares to commence trading today. Functional Brands Inc. is powered by Kirkman®, a legacy brand with over 75 years of trust from families and practitioners across 35+ countries. With an F
Household / Consumer / Cosmetics, Health
2025-11-05 8:00 AM EST | Functional Brands Inc.
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. The Company will host a webcast conference call on Decembe
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-05 7:45 AM EST | Cardiol Therapeutics Inc.